Comparing two gastric bypass surgeries for type 2 diabetes in severe obesity
Compares two bypass operations in adults with severe obesity and type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.
Key facts
- Where
- Amiens, Boulogne-sur-Mer, Lille, and Valenciennes, FranceSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT03821636, who can take part
Where in France
- Chu Amiens PicardieAmiens, FranceTaking people
- Ch Boulogne-Sur-MeBoulogne-sur-Mer, FranceTaking people
- Hop Claude Huriez Chu LilleLille, FranceTaking people
- CH de ValenciennesValenciennes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Lille
- Trial code
- NCT03821636
- Record updated
- 23 December 2025
- Original description
In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss. The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified. A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion. the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures. The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.Read full original descriptionShow less
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. A Prospective, Multicentric, Randomized, Controlled Trial.
In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss. The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified. A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion. the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures. The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.
Inclusion: BMI ≥ 35 kg/m2; All patient with type 2 diabetes; Patients who were candidates for obesity surgery in accordance with French recommendation.
Exclusion: patient who have already undergone obesity surgery; The absence of identified prior medical management of obesity; Severe cognitive or mental disorders; Severe and non-stabilised eating disorders; Diseases that are life-threatening in the short and medium term; The likely inability of the patient to participate in lifelong medical follow-up; Alcohol or psychoactive substances dependence; Contraindications to general anaesthesia.